U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07490132) titled 'Endoscopic Retrograde Cholangiopancreatography' on March 18.
Brief Summary: The risk of post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis(PEP) is influenced by patient and procedure-related factors. Strategies to decrease PEP(Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis) are of great importance.
Study Start Date: Feb., 2026
Study Type: OBSERVATIONAL
Condition:
Gastro-Intestinal Disorder
Intervention:
OTHER: Patients undergoing ERCPs at Methodist Dallas Medical Center
The registry will include all patients who meet registry inclusion. Enrollment will terminate once 25 years of data are...